Galectin Therapeutics Inc.
GALT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $15 | $26 | $19 | $40 |
| Short-Term Investments | $0 | $0 | $0 | $0 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $2 | $2 | $2 | $2 |
| Total Curr. Assets | $17 | $28 | $21 | $42 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $0 |
| Total NC Assets | $0 | $0 | $1 | $0 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $17 | $28 | $21 | $42 |
| Liabilities | – | – | – | – |
| Payables | $6 | $6 | $4 | $2 |
| Short-Term Debt | $21 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $9 | $9 | $9 | $7 |
| Total Curr. Liab. | $35 | $16 | $13 | $9 |
| LT Debt | $85 | $72 | $40 | $29 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $1 | $1 | $1 |
| Total NC Liab. | $85 | $73 | $40 | $30 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $121 | $88 | $53 | $39 |
| Equity | – | – | – | – |
| Pref Stock | $2 | $2 | $2 | $2 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$402 | -$354 | -$310 | -$271 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $296 | $292 | $275 | $271 |
| Total Equity | -$103 | -$60 | -$32 | $3 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $17 | $28 | $21 | $42 |
| Net Debt | $91 | $46 | $21 | -$11 |